CN110863031A - Marker for detecting treatment effect of brucellosis and application thereof - Google Patents
Marker for detecting treatment effect of brucellosis and application thereof Download PDFInfo
- Publication number
- CN110863031A CN110863031A CN201910936392.5A CN201910936392A CN110863031A CN 110863031 A CN110863031 A CN 110863031A CN 201910936392 A CN201910936392 A CN 201910936392A CN 110863031 A CN110863031 A CN 110863031A
- Authority
- CN
- China
- Prior art keywords
- marker
- brucellosis
- treatment
- detecting
- brucella
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 38
- 206010006500 Brucellosis Diseases 0.000 title claims abstract description 19
- 230000000694 effects Effects 0.000 title claims abstract description 19
- 239000003550 marker Substances 0.000 title claims abstract description 19
- 210000003979 eosinophil Anatomy 0.000 claims abstract description 31
- 241000589562 Brucella Species 0.000 claims abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000036760 body temperature Effects 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000002924 anti-infective effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000037000 normothermia Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to the technical field of medicines, in particular to a marker for detecting the treatment effect of brucellosis and application thereof. The invention aims to provide application of eosinophil level in predicting therapeutic effect of brucellosis, and particularly relates to evaluation of therapeutic effect of brucellosis patients by detecting eosinophil count and percentage. A marker for detecting the treatment effect of brucellosis, wherein eosinophils are adopted as the marker. The invention discloses for the first time: eosinophil count and proportion are reduced in brucella patients, and eosinophil count and proportion are gradually recovered after anti-infection treatment.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a marker for detecting the treatment effect of brucellosis and application thereof.
Background
Brucellosis (Brucellosis) is a natural epidemic disease, and is a bacterial infectious disease caused by Brucella and mainly derived from human and animals. Over the 21 st century, brucellosis in our country has shown a tendency to re-epidemic, with the affected areas expanding from northern pasturing areas to adjacent grassland and agricultural areas, and then to southern coastal and southwest areas. Brucella can invade human body through multiple transmission ways, can cause the hyperplasia of the reticuloendothelial system of the whole body, and is accompanied with the damage of multiple systems such as nerve, circulation, reproduction, immunity and the like, thereby causing the loss of the labor capacity of patients, and even becoming a main factor restricting the economic development in partial areas.
Brucella is an intracellular parasitic bacterium which is mainly propagated in reticuloendothelial system cells of a human body, and lack of proper treatment in an acute stage can cause Brucella to be colonized in each tissue organ cell to form intractable subacute or chronic infection, is similar to tuberculosis, is a granulomatous disease which can affect any organ, and needs long-term chemotherapy to achieve clinical cure. Once diagnosed, antibiotics with strong cell penetration should be given in time for combined application, sufficient amount, long treatment course or multiple treatment courses. If the treatment is not standardized, the delay is usually caused. In a few cases, organic damages to bones and joints can be left, so that the movement of limbs is limited, and in some cases, sequelae of the central nervous system appear, thereby causing great physical and psychological pain and economic burden to patients. More serious can lead to patient death, the main cause of death being endocarditis, serious neurological complications, etc. The treatment of chronic cases caused by untimely and incomplete diagnosis and treatment is complex and has poor treatment effect. At present, no effective index for predicting the antibacterial treatment effect of brucellosis exists, and clinical diagnosis and treatment cannot be guided.
Disclosure of Invention
The invention aims to provide application of eosinophil level in predicting therapeutic effect of brucellosis, and particularly relates to evaluation of therapeutic effect of brucellosis patients by detecting eosinophil count and percentage.
A marker for detecting the treatment effect of brucellosis, wherein eosinophils are adopted as the marker.
Evaluating the treatment effect of the brucellosis patient according to the detected eosinophil count and percentage; the disease condition of the brucella patients is predicted according to the content or the change trend of the content of the blood eosinophils.
Use of a marker for detecting the therapeutic effect and predicting the condition of a patient suffering from brucella.
Use of a reagent for detecting a marker in the preparation of a reagent for assessing the therapeutic effect or predicting the condition of a patient suffering from brucella.
The reagent for detecting eosinophil is leukocyte differential dye liquor (STROMMATOLYSER-4 DS, FFS-800A).
Use of a method for detecting a marker for assessing the treatment effect or predicting the condition of a patient suffering from brucella.
The method for detecting eosinophils is flow cytometry.
Wherein,
the detection marker is the detected eosinophil count and percentage.
The treatment effect refers to whether the body temperature of the patient is normal or not.
The disease condition of the patient with brucella is predicted according to the content of blood eosinophils or the change trend of the content of the blood eosinophils.
The method for predicting the treatment effect of brucellosis refers to judging the treatment effect by monitoring the blood eosinophil count and percentage of patients. The method is determined by dynamically monitoring blood routine during treatment of brucella patients.
The invention discloses for the first time: eosinophil count and proportion are reduced in brucella patients, and eosinophil count and proportion are gradually recovered after anti-infection treatment.
Drawings
FIG. 1 is a graph of eosinophil count and percentage levels before and after normothermia in a patient.
FIG. 2 is a graph of the patient's eosinophil count and percentage change during the course of treatment of the patient.
Detailed Description
For the purpose of facilitating understanding, the invention will be described in detail below with reference to specific drawings and examples. It is specifically intended that the specification and figures are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application. Such modifications and variations are intended to be included within the scope of the present invention.
The methods used in the following examples are conventional methods unless otherwise specified. Materials or reagents required in the following examples are commercially available unless otherwise specified.
Main apparatus and reagents: fully automatic blood analyzers (XE-2100, SYSMEX CORPORATION, Japan); diluent (cellack, PK-30L), sheath fluid (CELLSHEATH), basophilic hemolysin (STROMATOLYSER-FB, FBA-200A), leucocyte-sorting hemolysin (STROMATOLYSER-4DL, FFD-200A), leucocyte-sorting Stain (STROMATOLYSER-4DS, FFS-800A), nucleated erythrocyte Stain (STROMATOLYSER-NR, SNR-800), haemoglobin hemolysin (SULFOLYSER, SLS-220A), juvenile hemolysin (STROMATOLYSER-IM, SIM-220A), detergent (CELLCLEAN, CL-50), nucleated erythrosin (STROMATOLYSER-NR), reticulocyte diluent (RETSEARCH-II Dilution), reticulocyte Stain (RETSEARCH-II Stain). All reagents were from SYSMEX CORPORATION (Sysmex group).
Example 1
30 cases of patients with Brucella are used as samples, peripheral blood samples (EDTA anticoagulated) are collected before and after the patients are normothermic, and conventional blood detection is carried out by using a full-automatic blood analyzer (XE-2100, SYSMEX CORPORATION, Japan). Eosinophil levels were analyzed before and after normothermia of the patients after antibacterial treatment.
As shown in figure 1, the absolute count and percentage of peripheral blood eosinophils of brucella patients before treatment were significantly reduced and could be restored to normal after effective anti-infective treatment.
Example 2
Peripheral blood samples (EDTA anticoagulated) of 20 patients with Brucella whose body temperature was not normal before and after treatment and body temperature was normal after treatment were collected, and subjected to routine blood testing using a fully automatic blood analyzer (XE-2100, SYSMEX CORPORATION, Japan). Eosinophil levels were analyzed during the course of antimicrobial therapy until after normothermia in the patients.
As shown in figure 2, the absolute eosinophil count and percentage in peripheral blood of brucella patients were significantly reduced before treatment, and gradually restored after effective anti-infection treatment.
The combination of the above results indicates that eosinophil level can predict anti-infection treatment effect of Brucella patients.
Claims (8)
1. A marker for detecting the treatment effect of brucellosis is characterized in that: the marker is eosinophil.
2. The marker of claim 1, wherein: evaluating the treatment effect of the brucellosis patient according to the detected eosinophil count and percentage; the disease condition of the brucella patients is predicted according to the content or the change trend of the content of the blood eosinophils.
3. Use of the marker of claim 1 for detecting the effect of treatment and predicting the condition of patients with brucellosis.
4. Use of a reagent for detecting the marker of claim 1 for the preparation of a reagent for evaluating the effect of treatment or predicting the condition of a patient with brucella.
5. Use of a method for detecting a marker according to claim 1 for assessing the efficacy of a treatment or predicting the condition of a patient suffering from brucella.
6. Use according to claim 4 or 5, characterized in that: the detection marker is the detected eosinophil count and percentage.
7. Use according to claim 4 or 5, characterized in that: the treatment effect refers to whether the body temperature of the patient is normal or not.
8. Use according to claim 4 or 5, characterized in that: the disease condition of the patient with brucella is predicted according to the content of blood eosinophils or the change trend of the content of the blood eosinophils.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910936392.5A CN110863031A (en) | 2019-09-29 | 2019-09-29 | Marker for detecting treatment effect of brucellosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910936392.5A CN110863031A (en) | 2019-09-29 | 2019-09-29 | Marker for detecting treatment effect of brucellosis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110863031A true CN110863031A (en) | 2020-03-06 |
Family
ID=69652545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910936392.5A Pending CN110863031A (en) | 2019-09-29 | 2019-09-29 | Marker for detecting treatment effect of brucellosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110863031A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026191A1 (en) * | 2003-06-02 | 2005-02-03 | Julie Carman | Polynucleotides encoding novel guanylate binding proteins (GBP's) |
| US20100249019A1 (en) * | 2007-09-11 | 2010-09-30 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| CN102781468A (en) * | 2009-12-03 | 2012-11-14 | 西班牙高等科研理事会 | Method for the identification of animals vaccinated against brucella |
| CN106596958A (en) * | 2016-12-19 | 2017-04-26 | 中国兽医药品监察所 | Brucellosis CF-ELISA antibody detection kit |
| CN107001449A (en) * | 2014-10-15 | 2017-08-01 | 芝诺锡拉公司 | The composition of immunogenicity with reduction |
| CN107513575A (en) * | 2017-10-16 | 2017-12-26 | 内蒙古民族大学 | A kind of method and its application for detecting the bacterium infection of cloth Shandong |
-
2019
- 2019-09-29 CN CN201910936392.5A patent/CN110863031A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026191A1 (en) * | 2003-06-02 | 2005-02-03 | Julie Carman | Polynucleotides encoding novel guanylate binding proteins (GBP's) |
| US20100249019A1 (en) * | 2007-09-11 | 2010-09-30 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| CN102781468A (en) * | 2009-12-03 | 2012-11-14 | 西班牙高等科研理事会 | Method for the identification of animals vaccinated against brucella |
| CN107001449A (en) * | 2014-10-15 | 2017-08-01 | 芝诺锡拉公司 | The composition of immunogenicity with reduction |
| CN106596958A (en) * | 2016-12-19 | 2017-04-26 | 中国兽医药品监察所 | Brucellosis CF-ELISA antibody detection kit |
| CN107513575A (en) * | 2017-10-16 | 2017-12-26 | 内蒙古民族大学 | A kind of method and its application for detecting the bacterium infection of cloth Shandong |
Non-Patent Citations (3)
| Title |
|---|
| PENG-FEI JIAO ET AL.: "Expression of eosinophils be beneficial to early clinical diagnosis of brucellosis", 《INT J CLIN EXP MED》 * |
| 张斌等: "1例米诺环素治疗布鲁氏菌病致急性嗜酸性粒细胞性肺炎的分析", 《中国临床药理学杂志》 * |
| 薛继华等: "25例布鲁菌病的临床特征分析", 《中国临床药理学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gardner et al. | The validity of the clinical signs and symptoms used to identify localized chronic wound infection | |
| Steeneveld et al. | The influence of cow factors on the incidence of clinical mastitis in dairy cows | |
| Cameron et al. | Evaluation of selective dry cow treatment following on-farm culture: Risk of postcalving intramammary infection and clinical mastitis in the subsequent lactation | |
| Trachtman et al. | Isolated hematuria in children: indications for a renal biopsy | |
| Vaarst et al. | Patterns of clinical mastitis manifestations in Danish organic dairy herds | |
| Zervos et al. | Diagnosis of ventricular shunt infection in children: a systematic review | |
| Shi et al. | Skin status for predicting pressure ulcer development: a systematic review and meta-analyses | |
| Mauro et al. | Postmortem urinary tract changes in cats with urethral obstruction | |
| Huang et al. | Association between differential somatic cell count and California Mastitis Test results in Holstein cattle | |
| JP6193976B2 (en) | Clostridium difficile dehydrogenase and toxin as biomarkers | |
| CN110863031A (en) | Marker for detecting treatment effect of brucellosis and application thereof | |
| Lefrère et al. | Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis | |
| Rothenbacher et al. | Active infection with Helicobacter pylori in an asymptomatic population of middle aged to elderly people | |
| Heldwein et al. | Antibiotics and observation have a similar impact on asymptomatic patients with a raised PSA | |
| Hines et al. | Adjustment of cerebrospinal fluid protein for red blood cells in neonates and young infants | |
| Tariq et al. | Feline lower urinary tract disease (FLUTD)–an emerging problem of recent era | |
| Barati et al. | Early prediction of renal parenchymal injury with serum procalcitonin | |
| Merritt et al. | Limitations of the antibody-coated bacteria test in patients with neurogenic bladders | |
| Brooks et al. | Cerebrospinal fluid white cell count to red cell count ratio as a predictor of ventriculitis in patients with external ventricular drains | |
| Smith III et al. | Quantitation of reticulated platelets in healthy dogs and in nonthrombocytopenic dogs with clinical disease | |
| Forman et al. | Reevaluation of the ambulatory pediatric patient whose blood culture is positive for Haemophilus influenzae type b | |
| Chapman et al. | The utility of screening laboratory studies in pediatric patients with sickle cell pain episodes | |
| Motokura et al. | Severe Legionella pneumonia in which serial testing by Ribotest® Legionella was useful for the diagnosis | |
| Saravanan et al. | Survey on urinary tract infection associated with diabetes mellitus | |
| Hejlesen et al. | Decision Support for Diagnosis of Lyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |